4.6 Article

Rapid isolation of antigen-specific B-cells using droplet microfluidics

Journal

RSC ADVANCES
Volume 10, Issue 45, Pages 27006-27013

Publisher

ROYAL SOC CHEMISTRY
DOI: 10.1039/d0ra04328a

Keywords

-

Funding

  1. UCB Pharma (Berkshire, UK)
  2. NIH SBIR [1 R43 AI082861-01, 5R43GM113420-02]
  3. Harvard University Blavatnik Biomedical Accelerator award
  4. Massachusetts Life Sciences Center (MLSC) Cooperative Research Matching Grant
  5. NIH SBIR grant [5R43GM113420-02]
  6. European Social Fund [09.3.3-LMT-K-712-01-0056]
  7. DARPA award [HR0011-11-C-0093]
  8. Bill and Melinda Gates Foundation [OPP1126222]
  9. UCB Pharma, Inc. [A19019]
  10. Total S.A. [A21376]
  11. Capsum award [A28393]
  12. Cytonome award [A21447]
  13. Solvay Pharmaceuticals [A19372-A20360]
  14. NCI Cancer Center support grant [2P30CA006516-48]
  15. Bill and Melinda Gates Foundation [OPP1126222] Funding Source: Bill and Melinda Gates Foundation

Ask authors/readers for more resources

Monoclonal antibodies are powerful tools for scientific research and are the basis of numerous therapeutics. However, traditional approaches to generate monoclonal antibodies against a desired target, such as hybridoma-based techniques and display library methods, are laborious and suffer from fusion inefficiency and display bias, respectively. Here we present a platform, featuring droplet microfluidics and a bead-based binding assay, to rapidly identify and verify antigen-binding antibody sequences from primary cells. We used a defined mixture of hybridoma cells to characterize the system, sorting droplets at up to 100 Hz and isolating desired hybridoma cells, comprising 0.1% of the input, with a false positive rate of less than 1%. We then applied the system to once-frozen primary B-cells to isolate rare cells secreting target-binding antibody. We performed RT-PCR on individual sorted cells to recover the correctly paired heavy- and light-chain antibody sequences, and we used rapid cell-free protein synthesis to generate single-chain variable fragment-format (scFv) antibodies from fourteen of the sorted cells. Twelve of these showed antigen-specific binding by ELISA. Our platform facilitates screening animal B-cell repertoires within days at low cost, increasing both rate and range of discovering antigen-specific antibodies from living organisms. Further, these techniques can be adapted to isolate cells based on virtually any secreted product.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available